Prolastin-C Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to approval for metastatic renal cell carcinoma, early success of immunotherapy approaches, hospital oncology adoption, limited historic immunotherapy options, specialist administration protocols.

The growth in the forecast period can be attributed to growth of cancer immunotherapy research, renewed interest in cytokine therapies, combination treatment strategies, expansion of oncology centers, personalized cancer care focus. Major trends in the forecast period include continued use of cytokine based immunotherapy, application in advanced oncology care, hospital based il-2 administration, niche use in immuno oncology, combination with other cancer therapies.

The rising incidence of respiratory infections is expected to drive the growth of the Prolastin-C market in the coming years. Respiratory infections affect the respiratory system, including the nose, throat, airways, and lungs, and are caused by pathogens such as viruses, bacteria, fungi, or other microorganisms. The increase in respiratory infections is fueled by emerging viral strains, seasonal changes, weakened immune systems, environmental pollution, and increased human mobility. Prolastin-C, an alpha-1 antitrypsin (AAT) replacement therapy, helps manage respiratory diseases, particularly COPD related to alpha-1 antitrypsin deficiency, by replenishing the deficient AAT protein. This therapy reduces lung inflammation, protects against tissue damage caused by protease activity, and improves lung function and overall respiratory health in affected patients. For example, in October 2024, the National Asthma Council, an Australia-based non-profit organization, reported that Australia recorded 474 asthma-related deaths in 2023 - 325 females and 149 males - nearly identical to the 473 deaths reported in 2022, reflecting a consistent trend in asthma mortality. Therefore, the rising incidence of respiratory infections is driving the Prolastin-C market.

Increasing research and development expenditure is also expected to support the growth of the Prolastin-C market. Research and development (R&D) includes organized activities conducted by companies, organizations, or individuals to generate new knowledge, develop innovative products, or improve existing therapies and processes. R&D expenditure is rising due to technological advancements, increasing demand for innovation, and the need to develop new therapies in competitive markets. Higher R&D investment benefits Prolastin-C by enabling advanced clinical trials, improving efficacy, and accelerating the development of optimized formulations or dosing regimens to enhance patient outcomes. For example, in February 2025, the National Center for Science and Engineering Statistics (NCSES), a US-based government agency, reported that U.S. R&D expenditures rose from $892 billion in 2022 to $940 billion in 2023, an increase of $48 billion. Therefore, rising research and development expenditure is driving the Prolastin-C market.

Leading companies in the Prolastin-C market are focusing on clinical trials to evaluate safety and effectiveness. Clinical trials are research studies designed to assess the safety, efficacy, and potential side effects of new drugs, treatments, or medical devices in human participants. For instance, in July 2023, Grifols SA, a Spain-based pharmaceutical company, announced it had reached its enrollment target of 339 patients in the SPARTA (Study of Prolastin-C Randomized Therapy with Alpha-1 Augmentation) Phase 3 clinical trial. This study aims to determine whether patients with emphysema caused by alpha-1 antitrypsin deficiency experience a slower rate of lung tissue loss when treated weekly with two different dose regimens of Prolastin-C. The trial evaluates the therapy’s effectiveness in reducing emphysema progression by increasing AAT protein levels through weekly administration of two active doses (60 and 120 mg/kg) compared with a placebo.

Major companies operating in the prolastin-c market are Grifols S.A.

North America was the largest region in the prolastin-C market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prolastin-c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prolastin-c market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the proleukin market by increasing costs of recombinant protein production inputs and sterile manufacturing supplies. These impacts are seen primarily in oncology hospitals across Europe and Asia Pacific. Import duties have contributed to higher costs for biologic immunotherapies used in advanced cancers. Distribution timelines have also been affected due to regulatory clearance processes. At the same time, tariffs are encouraging localized biologics manufacturing and strengthening regional oncology drug supply resilience.

The prolastin-c market research report is one of a series of new reports that provides prolastin-c market statistics, including prolastin-c industry global market size, regional shares, competitors with a prolastin-c market share, detailed prolastin-c market segments, market trends and opportunities, and any further data you may need to thrive in the prolastin-c industry. This prolastin-c market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prolastin-C is a purified alpha-1 proteinase inhibitor (also called alpha-1 antitrypsin or AAT) derived from human plasma. It is primarily used as augmentation therapy for individuals with alpha-1 antitrypsin deficiency (AATD), a genetic condition that can lead to serious lung diseases such as emphysema. Prolastin-C increases alpha-1 antitrypsin levels in the blood and lungs, protecting lung tissue from damage caused by neutrophil elastase, an enzyme that can degrade lung elasticity when uncontrolled.

The main forms of Prolastin-C are 20 mL and 40 mL. The 20 mL formulation is a sterile, ready-to-use liquid intended for intravenous infusion in patients with alpha-1 antitrypsin deficiency. Its indications include chronic obstructive pulmonary disease (COPD), liver disease, pulmonary disease, and other related conditions. Prolastin-C is administered in settings such as hospitals and pharmacies.

The prolastin-C market consists of sales of inhalable pulmonary medications, nutritional supplements and other related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.